Overview
Wearable medical device firm's fiscal Q2 revenue rose 53%, beating analyst expectations
Adjusted EBITDA loss for fiscal Q2 beat analyst estimates
Outlook
Kestra increases FY26 revenue guidance to $91 mln, up from $88 mln
Company focuses on expanding commercial organization and wearable defibrillator market
Result Drivers
MARKET EXPANSION - Revenue growth driven by higher market share and WCD market expansion
GROSS MARGIN IMPROVEMENT - Gross margin expanded to 50.6% due to volume leverage and higher in-network patient mix
OPERATIONAL PROGRESS - Progress in commercial expansion and revenue cycle management supported results
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $22.57 mln | $20.70 mln (6 Analysts) |
Q2 EPS | -$0.64 | ||
Q2 Adjusted EBITDA | Beat | -$19.68 mln | -$20.56 mln (6 Analysts) |
Q2 Gross Profit | $11.42 mln | ||
Q2 Income from Operations | -$31.76 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Kestra Medical Technologies Ltd is $28.00, about 14.2% above its December 10 closing price of $24.52
Press Release: ID:nGNXbdHzb2
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)